Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Study of Gemcitabine Versus TS-1 Versus Gemcitabine Plus TS-1 in Unresectable Advanced Pancreatic Cancer (With Local Progression or Metastasis)

NCT00498225 is registered in ClinicalTrials.gov with Taiho Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT00498225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00498225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Study of Gemcitabine Versus TS-1 Versus Gemcitabine Plus TS-1 in Unresectable Advanced Pancreatic Cancer (With Local Progression or Metastasis)
Lead sponsor
Taiho Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2007
Completion date
June 30, 2012
Enrollment
834 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer